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Abstract 
Background: Influenza viruses are a significant cause of morbidity and mortality. The influenza virus pandemics, 
1918, 1977, and especially the most recent one, A/H1N1/2009, made evident the need for generating recombinant 
Influenza H1N1 antigens which are essential to develop both basic and applied research programs. Among influenza 
virus proteins, haemagglutinin (HA) is a major surface antigen of influenza virus, thus it is highly topical in 
influenza research and vaccine engineering programs. Alternatively, expression of fragments of the HA (HA1 and 
HA2) proteins in prokaryotic systems can potentially be the most efficacious strategy for manufacture of large 
quantities of influenza vaccine in a short period of time.  
Materials and Methods: The gene encoding the HA1 protein of  the influenza A/Puerto Rico/8/34 was amplified 
by PCR, then cloned into pTZ57R/T cloning vector. The fidelity of the HA1 open reading frame was confirmed by 
bidirectional sequencing, then sub-cloned into pET28a prokaryotic expression plasmid, and proteins containing HA1 
N-terminally fused to His-Tag were produced in Escherichia coli BL21 through IPTG inducing. The accuracy of the 
expression was confirmed by running time coursed fraction samples taken before and after the IPTG induction in 
SDS-PAGE, Western blot analysis were also used for confirmation of the recombinant protein.  
Results and Conclusion: The HA1 protein produced here could be considered and evaluated as a protective 
antigen, which its immunogenicity potential needs to be assessed in animal models along with proper control groups. 
Moreover, it could be subjected for polyclonal antibody preparation, which, in turn, may be used as an essential 
material in western blot analyses, as well as in other immunological applications, such as ELISA, 
immunocytochemistry, immunohistochemistry, and other immunological and serological studies. 
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Influenza is considered to be one of the most 
severe threats to human health and animal welfare. In 
temperate climates, seasonal epidemics occur mainly 
during winter while in tropical regions, influenza 
may occur throughout the year, causing outbreaks 
more irregularly. Influenza occurs globally with an 
annual attack rate estimated at 5%–10% in adults and 
20%–30% in children (1). 
All commercial influenza vaccines are produced 
by propagating the virus in embryonated chicken eggs 
(2).Their production system has some limitations, such 
as the need for specific pathogen-free (spf) 
Prokaryotic Expression of H1N1 Influenza A Virus Haemagglutinin Protein Globular Domain (HA1)           Bahreinian et al. 
Vol 2, No 3,  Summer 2016 
95 
embryonated eggs, required time for adaptation to the 
new circulating virus subtypes, long production time, 
and limited capacity(3).Further processing is also 
needed to separate and inactivate viral particles and 
to purify the haemagglutinin (HA) protein, the 
primary vaccine antigen. This technology is slow and 
requires one embryonated egg per vaccine dose (2). 
Several alternative strategies have been 
proposed to produce pandemic and seasonal 
influenza vaccines, but the expression and 
purification of a single antigenic protein in bacteria 
culture may be the simplest and fastest strategy for 
generating large quantities of new influenza vaccines 
(4). Moreover, recombinant vaccines produced in 
bacteria, free of other viral and cellular components, 
are expected to reduce complications associated with 
whole virus vaccines such as pyogenic reaction and 
Guillain-Barre syndrome (5). 
Influenza A viruses are single stranded, 
negative-sense RNA viruses, comprising eight 
genome segments that are enveloped by a lipid 
bilayer containing haemagglutinin (HA) and 
neuraminidase (NA) glycoproteins. Both surface 
proteins are targeted by human humoral immunity 
(6), but haemagglutinin is the most abundant 
glycoprotein on the surface of influenza viruses (7), 
approximately 25% of total viral protein (8), and 
functions in viral entry into the host cell (9-11). 
HA is synthesized as a precursor polypeptide 
HA0 in the endoplasmic reticulum, where it is 
assembled into trimers (3), and this homotrimer has a 
receptor binding pocket on the globular head of each 
monomer (12). Then, via the Golgi network, HA 
trimer is exported to the cell surface where it is 
cleaved by host proteases into two subunits: HA1 and 
HA2. The HA1 subunit forms a globular head which 
contains the receptor binding site, a main target for 
neutralizing antibodies (3, 13). 
Antibodies reactive toward HA have been 
associated with host resistance and a decrease in 
disease severity. It has been shown that 60% of 
antibodies produced during an influenza infection are 
reactive toward the HA protein (9). Antibodies 
against HA protein block virus attachment, thereby 
decreasing the number of cells infected. They can 
also function to prevent fusion (12). Thus, only 
neutralizing antibodies directed against the HA 
glycoprotein are the primary mediators of protection 
against influenza virus infection (6, 14, 15), and are 
most effective in vivo (12). 
As mentioned above, each HA monomer 
consists of an HA1 and an HA2 subunit. The HA1 
subunit contains the receptor-binding site that 
mediates viral attachment to the cell membrane, 
whereas the HA2 subunit contributes to membrane 
fusion (6, 15, 16). The HA1 domain contains most of 
the antigenic sites and is more prone to mutations and 
antigenic drift than other parts of the protein (6, 17). 
Researches have also shown that HA1 fragment, rather 
than HA2, is the site of HA and host cell interactions, 
and the majority of the antibodies are reactive against 
HA1(6, 8). 
That was why we have chosen to work on the 
globular head of the HA protein, HA1, which has 
more important role in attachment to the host cell, so 
in contrast with virus other proteins, blocking it could 
be happened before the infection of the host cell 
happens, and against which most human antibodies are 
made during an influenza infection (9). 
One concern may be that complete viral particle 
may be more immunogenic than recombinant peptides 
because the former are poly-antigenic and undergo 
post-transcriptional modifications such as 
glycosylation. But the researches have shown that 
glycosylation is not a mandatory requirement for 
influenza vaccine efficacy (4). 
Methods 
Viral RNA extraction and Reverse-
transcription. Influenza A virus (A/Puerto Rico/8/34 
(H1N1)), has been propagated on Madin-Darby 
Canine Kidney (MDCK) cell line,supplemented with 
5% fetal calf serum (FCS), to increase the viral titerto 
512 HAU/ml (Haemagglutinin Unite). Total RNA was 
extracted from 200 µl of the supernatant of infected 
MDCK cells using Invitrogen PureLink® Viral 
RNA/DNA Mini Kit (cat# 12280-050). 
Amplification of HA1 gene by RT-PCR. To 
perform RT-PCR, 50 µl of the extracted RNA is first 
converted into cDNA using M-MuLV reverse 
Transcriptase (Fermentas cat# EP0451) and the 
universal primer (uni 12), introduced for amplification 
of all genomic fragments of all influenza A strains (5’-
AGCAAAAGCAGG-3’) (18). 
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The HA1 gene (978 bp) was specifically 
amplified by PCR of the cDNA, using High Fidelity 
(Fermentas,cat#K0191) enzyme and two synthetic 




ATGTTC-3’). As underlined in the reverse primer, a 
termination codon has been designed on the reverse 
primer, because trough the influenza virus infection, 
the HA gene is being translated intact, and the 
cleavage between the two fragments (HA1 and HA2) 
happens afterwards. That is why HA gene itself has 
the termination codon on the end of the HA2 
segment, and not in the end of HA1 fragment. 
According to our cloning strategy,a restriction 
enzyme cut site, NheI sequence, and another 
restriction enzyme cut site, Sall sequence, was 
introduced in the forward and reverse primers 
respectively. 
Amplification reaction was carried out under 
the following profile: 3 min at 95°C followed by 31 
cycles at 95°C for 30 sec. 58°C for 30 sec, and 72°C 
for 60 sec, with a final extension step at 72°C for 10 
min. 
Then the PCR products were analyzed on 1% 
(w/v) agarose gel electrophoresis. 
Cloning and subcloning of HA1. PCR 
products were cleaned up by QIAquick PCR 
Purification Kits (QIAGEN cat#2810), and were 
cloned into pTZ57R/T cloning vector InsTAclone 
PCR Cloning Kit (Fermentas cat# k1213). 
The recombinant vectors were transformed 
into E.coli DH5ɒ Calcium Chloride competentcells, 
then the clones were screened by choosing white 
colonies among blue/white bacteria colonies grew on 
the culture plate. The insertion of the interested 
sequence was confirmed by Colony-PCR on the 
selected white colonies, along with one blue colony 
as a negative control. Taq DNA Polymerase 2x 
Master Mix Red (Ampliqon cat#180301) and HA1 
specific primers were used in the Colony-PCR. The 
recombinant vector pTZ57R/T+HA1 was confirmed 
using restriction enzyme analysis, and subsequently, 
it was subjected to automatic sequencing 
bidirectionally using M13 universal primers. 
The HA1 gene was excised from the 
confirmed clones by NheI/BamHI double digestions, 
and then cloned into prokaryotic expression vector 
pET28a (Novagen),linearized with the same 
digestions, in order to create the HA1 expression 
plasmid pET28a+HA1 (Fig. 1). The fidelity of 
pET28a+HA1 was confirmed by colony PCR and 
vector restriction map (Fig. 4). 
All DNA manipulations including double 
digestion, T4 ligation, and agarose gel electrophoresis 
were carried out as described by Sambrook and 
Russell(19). 
Expression of HA1 recombinant protein. The 
pET28a+HA1 transformed into the E.coli BL21 
(λDE3) (Novagen) competent cells. After culturing 
transformed cells on LB-agar plates containing 
50μg/ml kanamycin at 37°C overnight, one colony 
was inoculated in 15ml of LB medium supplemented 
with 50μg/ml kanamycin, and incubated until reaching 
to 0.5 to 1 optical density at 600nm. 
The cultures were induced by isopropyl-β-D-
galactoside (IPTG) at a final concentration of 1mM 
afterwards. Time course fractionating from cultures 
started before inducing and continued for 4 hours at 
37°C temperature. 
SDS-PAGE and Western Blotting. To assess 
His-tagged proteins, total bacterial cell proteins (TCP) 
were subjected to 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
beside of protein ladder (Fermentas/cat#SM0431). 
Acrylamide gel staining was performed by Coomassie 
brilliant blue R-250. 
For further characterization, the separated 
proteins on SDS-PAGE were transferred electrically to 
nitrocellulose membrane and blocked with Tris-
buffered saline-Tween (TBST) + 1% Bovin Serum 
Albumin (BSA) at 4°C overnight, then probed with 
Anti-His6 monoclonal antibody Peroxidase Conjugate 
(Roche Cat#04 905 318 001) diluted 1:300 in TBS-T, 
for 90 min on the shaker at room temperature. After 
washing with TBS-T, the specific protein bands were 
visualized using diaminobenzidine (DAB substrate) 
(Sigma Cat#D5637). 
Results 
HA1 gene was amplified successfully from the 
cDNA using designed primers. Figure 2 shows the 
formation of 999 bps amplicons compared to the DNA 
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molecular weight marker, and no signal was 
observed in the negative control. 
The accuracy of the pTZ57R/T+HA1 vector 
was confirmed through Colony PCR, restriction map 
analysis, using single digesting with XhoI, KpnI, 
BamHI and PaeI (SphI), along with double digesting 
with NheI/BamHI(Fig. 3), and also through DNA 
sequencing. Results also demonstrated the absence of 
amino acid substitution when aligned with the 
counterpart region from influenza A virus strain 
A/Puerto Rico/8/34. 
pTZ57R/T+HA1 Plasmid construct was 
verified using Colony PCR with HA1 specific 
primers (Fig. 4), and restriction enzyme digestion 
(Fig. 5). As demonstrated in Fig.5, restriction 
enzyme digestion also verified the sub cloning of 
HA1 into pET28a, resulting in the formation of 
pET28a+HA1. 
E. coli strain BL21 (λDE3) harboring 
pET28a+HA1 was cultured from HA1 protein 
expressionist’s-PAGE of TCP for HA1 protein on 4-
12% polyacrylamide gel demonstrated the expected 
size equal to 38.39 KDa, showed in Fig. 6, in which 
it is evident that before induction, target protein had 
not been expressed, but as the IPTG was added to the 
culture medium, the recombinant protein expression 
was started and increased during time courses.  
HA1 protein sample was further confirmed 
through Western blotting, conducted by Anti-His6 
monoclonal antibody Peroxidase conjugate, and the 
expected polypeptide band, which wasN-terminally 
His-tag fused with a molecular weight of about 38.39 
kDa (Fig. 7).  
Discussion 
The H1N1 influenza subtype is a significant 
viral agent affecting public health and has been 
responsible for 3 pandemics and several influenza 
epidemics globally. As the H1N1 virus has been 
suggested to become potentially a seasonal influenza 
agent with annual outbreaks, development of rapid, 
convenient and specific laboratory diagnosis seems 
necessary to treat patients efficiently and prevent the 
virus spreading (6). 
The structures of HA antigenic sites vary not 
only among different subtypes of viruses but also 
 
Figure 1. Construction ofpET28a+HA1. Schematic representation of 
cloned HA1 in pET28a, containing an N-terminal 6 histidine tag. 
 
 
Figure 2. 1% agarose gel electrophoresis of HA1 PCR product. All 2 
to 5 numbered lanes are HA1 amplicons, and 6th lane is no template 
control (NTC). GeneRuler 1kb DNA Ladder (Fermentas 
Cat#SM0313) has been used. 
 
 
Figure 3. pTZ57R/T+HA1 plasmid restriction enzyme analysis on 1% 
agarose gel electrophoresis. Lane 2, pTZ57R/T+HA1 single digested by 
BamHI, 3885 bps; lane 3: pTZ57R/T+HA1 single digested by KpnI, 
3885 bps; lane 4, pTZ57R/T+HA1 double digested by PaeI, resulting in 
two bands, 3270 bps and 615 bps; lane 5, pTZ57R/T+HA1 single 
digested by XhoI, 3885 bps; GeneRuler 1kb DNA Ladder (Fermentas  
Cat#SM0313)has been used. 
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within the same subtype. The continuous antigenic 
drifts and occasional antigenic shifts that arise from 
this continuous evolutionary variation enable human 
influenza viruses to escape the human immune system.  
(20) That is why, HA1 part of this membrane protein 
containing its major, constantly changing epitopes, 
represents a potential candidate for the discriminative 
diagnosis of H1N1 infection; and demonstrates the 
need for these priming studies in order to help 
complementing our knowledge about biochemical, 
immunological and serological aspects of influenza 
HA1 protein. 
Recombinant proteins are the most common 
source of the diagnostic reagents.(6)While each of 
mammalian, insect, and bacterial expression systems 
has its advantages (21), the bacterial expression 
system is one of the most universally used (6). This 
system has been employed widely due to multiple 
factors, including its relatively inexpensive cost, ease 
of manipulation and rapid growth rate (22). 
The reason that we chose pTZ57R/T as our 
cloning vector was that Taq DNA polymerase 
enzymes add a single 3’-A overhang at the both ends 
of the PCR product. The structure of these PCR 
products favors direct cloning into a linearized cloning 
vector with single 3’-ddT overhangs. Such overhangs 
at the vector cloning site not only facilitate cloning, 
but also prevent the recircularization of the vector. As 
a result, more than 90% of recombinant clones contain 
the vector with an insert (23). Recombinant clones 
were then selected based on blue/white screening. 
Then, considering the type of the target protein, 
our cloning method, ongoing application of the 
expressed protein, and its further extraction and 
purification, we choose pET28a as our expression 
vector.  
The pET system is one of the powerful 
expression systems for recombinant proteins in E. coli 
 
Figure 4. Colony-PCR Results of Cloning the HA1 in pET28a. Lane 2, 4, 5, 7: colonies containing HA1 gene, with the amplified band standing at 999 




Figure 5.Restriction enzyme analysis ofpET28a+HA1 on 1% agarose 
gel electrophoresis. Lane 1, Undigested pET28a+HA1 plasmid; lane 2, 
3: XhoI double digested pET28a+HA1 plasmids; GeneRuler 1kb DNA 




Figure 6.12% acrylamide gel electrophoresis of TCP collected 
fractions through specific time courses before and after induction. 
Lane 1, before IPTG induction; lane 2 to 6, collected samples 30 
min, 1h, 2h, 3h and 4h after IPTG induction, respectively; lane 7, 
Prestained Protein Ladder (SinaClon Cat#PR901641). 
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prokaryotic cell. Its expression system is restrictedly 
under the control of bacteriophage T7 lac promoter, 
which would be induced by IPTG, for providing T7 
RNA polymerase in host cell, in order to start the 
recombinant protein expression (24). 
Problematically, inclusion bodies of the 
membrane proteins, such as the HA protein may be 
often produced with incorrect folding using the 
bacterial system and require denaturation and 
renaturation before further use. These processes may 
complicate or inhibit recombinant protein production. 
As a result, the use of low culture temperature, co-
expression of molecular chaperones and proper host 
strain of E. coli has been suggested to promote the 
soluble expression of recombinant proteins. Hence, 
to further increase the recombinant protein solubility, 
the E. coli BL21 (DE3) has been chosen as the host 
strain, because it has previously demonstrated to be 
appropriate (25). 
The results showed that the designed primers 
have properly amplified the desired gene, and 
according to the sequencing results, the gene has 
properly been cloned in pTZ57R/T cloning vector. 
The recombinant expression vector restriction map 
also showed the authenticity of sub-cloning the 
desired gene, and an increasing pattern in target 
protein expression was observed in SDS-PAGE 
analysis through a time course at the expected protein 
weight, and the genuineness of the result recombinant 
protein was confirmed by Western Blotting results, 
showing the prosperity in achieving the prokaryotic 
expression of our desired protein. Our final expressed 
protein contains His. Tag which can help purifying it 
more easily for further investigations.  
In spite of the problems faced in expressing a 
viral native gene in a prokaryotic system, mostly 
caused by codon usage, we importantly could have 
expressed HA1 gene in E.Coli. Studies show that, 
despite not being glycosylated in this host, this protein 
can be refolded to its immunogenic structure, and also 
induce immune responses (4). But since lack of 
glycosylation, most of the recombinant HA proteins 
expressed by E. coli could not agglutinate human 
RBCs (6), and then the product of this expression 
method could not still be coated on ELISA plates in 
order to replace current conventional hemagglutination 
inhibition (HI) assays (26). In the meanwhile, the 
recombinant HA1 protein produced in this study can 
be used for specific polyclonal antibody production in 
order to be utilized in immunological tests like 
Western blotting and Eliza. This protein would 
possibly be very useful for H1N1 virus infection 
surveys; and also after being purified from LPS and 
passing animal tests, it can be used for the screening of 
individuals for vaccination .  
As a result, it can also be argued that modifying 
the incubation temperature and time, and also the 
inducer concentration is suggested to prevent inclusion 
bodies. After having done all the required in  silico 
conformational and epitope studies, fusing the HA1 
protein to a molecular adjuvant (like C-terminal 
HSP70 and Flic) can be proposed as well, in order to 
increase its immunogenicity. It can also be suggested 
to fuse the HA1 protein to nanoparticles in other to use 
it in vivo as a nano-composite, and investigate it in 
further animal trial studies. 
Since the Influenza virus is a respiratory tract 
infection agent, antibodies induced by vaccine that 
restrict replication throughout the upper and lower 
respiratory tract are desired. So it might be more 
logical to direct its vaccinology studies toward 
producing mucosal antibodies in order to achieve 
faster and more effective prevention of its infection, 
because mucosal antibodies are evidently more 
 
Figure 7. Detection of the recombinant HA1 protein by Western blot 
analysis using Anti-His6 monoclonal antibody Peroxidase Conjugate. 
Lane 1, TCP sample of transformed cells before IPTG induction; lane 
2, TCP 4h after IPTG induction, showing expected 38.39 kDa 
HA1+His-tag protein size; lane 3, A known His-tagged protein 
sample weighed 48 kDa, used as positive control for WB procedure; 
lane 4, Prestained Protein Ladder (SinaClon Cat#PR901641). 
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effective than systemic antibodies in restricting 
replication of influenza virus in upper respiratory 
tract (12). 
Conclusion 
In the current study, we investigated the 
probability of expressing the HA1 globular domain 
instead of the intact gene, so in future studies, after 
doing all the required in silico studies, the probability 
of expressing the most important epitopes of HA can 
be investigated, in order to reduce the expenses of 
large-scale vaccine production. Also, this study can 
potentially be a primary step toward modern 
recombinant influenza vaccine production inside 
Iran, as the vaccine is the most effective way to 
prevent infection, especially because of not being 
able to prevent this infection transmission when 
occurring in a society.  
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